HLA-J (human leukocyte antigen J) (HLA-J)

HLA-J is a gene in the major histocompatibility complex (MHC) class I region of chromosome 6. For decades, it has been regarded as a pseudogene—a DNA sequence similar to a gene but generally believed not to produce a functional protein. Recent research indicates that HLA-J, while sequence-deleted and truncated, may be transcribed and that some HLA-J transcripts possess an alternative start codon, potentially leading to the expression of a protein lacking typical peptide-binding and transmembrane domains. This protein, if expressed, would likely not present antigenic peptides but might have immune-modulatory roles outside classical antigen presentation, such as secreted immune regulation. Its precise biological function remains speculative and unconfirmed in standard immunology. HLA-J is not a recognized therapeutic target, receptor, or enzyme and is not classically druggable, though it has been studied as a prognostic biomarker in select cancer contexts. Additional context and limitations: The term "major histocompatibility complex, class I, J" is not standard; HLA-J is not a canonical classical class I MHC molecule like HLA-A, -B, or -C but is sometimes grouped under non-classical or "other" class I-like genes/pseudogenes. HLA-J lacks critical domains for membrane expression and antigen presentation due to frame shifts and exon deletions. Its potential secretion and immunoregulatory roles are recent theoretical proposals only. Standard references, including NCBI, OMIM, and UniProt, typically classify HLA-J as a pseudogene or a non-functional gene. No drugs have been developed to target HLA-J, there are no validated clinical biomarkers based on it, and there are no related safety concerns. The abbreviation "CDA12" and "HLA-59" are rare and not used in primary immunology or clinical literature. Summary: HLA-J is most accurately classified as a non-classical, putative MHC class I pseudogene, not a functional receptor, enzyme, or conventional therapeutic target. There is some new evidence for transcription and possible secreted protein expression, but its function remains unclear and speculative, and it is not a validated target in pharmacology or clinical practice.

Other names

CDA12HLA-59

Not applicable